



UNIVERSITÀ
DEGLI STUDI
FIRENZE

FLORE

Repository istituzionale dell'Università degli Studi di Firenze

Incremental prognostic value of multiparametric echocardiographic assessment for severe aortic stenosis

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

Incremental prognostic value of multiparametric echocardiographic assessment for severe aortic stenosis / Nistri S.; Olivotto I.; Faggiano P.; Antonini-Canterin F.; Locantore E.; Papesso B.; Brigido S.; Cioffi G.; Rossi A.; Otto C.M.. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - ELETTRONICO. - 172:(2014), pp. 0-0. [10.1016/j.ijcard.2013.12.302]

Availability:

The webpage <https://hdl.handle.net/2158/1181503> of the repository was last updated on 2020-01-09T11:32:15Z

Published version:

DOI: 10.1016/j.ijcard.2013.12.302

Terms of use:

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

Publisher copyright claim:

La data sopra indicata si riferisce all'ultimo aggiornamento della scheda del Repository FloRe - The above-mentioned date refers to the last update of the record in the Institutional Repository FloRe

(Article begins on next page)

HEART

and Education in Heart

Incremental Prognostic Value of Multiparametric Echocardiographic Assessment for Severe Aortic Stenosis

Journal:	<i>Heart</i>
Manuscript ID:	Draft
Article Type:	Original article
Date Submitted by the Author:	n/a
Complete List of Authors:	Nistri, Stefano; CMSR Veneto Medica, Cardiology Sevice Olivotto, Iacopo Faggiano, Pompilio Antonini Canterin, Francesco; Ospedale Civile, A.R.C, Cardiology Locantore, Elisa Papesso, Barbara Brigido, Silvana; Ospedale Civile, A.R.C, Cardiology Cioffi, Giovanni Rossi, Andrea
Keywords:	AORTIC VALVE DISEASE < VALVULAR DISEASE, TRANSTHORACIC < ECHOCARDIOGRAPHY < IMAGING AND DIAGNOSTICS

SCHOLARONE™
Manuscripts

Incremental Prognostic Value of Multiparametric Echocardiographic Assessment for Severe Aortic Stenosis

Stefano Nistri¹, Iacopo Olivotto², Pompilio Faggiano³, Francesco Antonini-Canterin⁴, Elisa Locantore³, Barbara Papesso¹, Silvana Brigido⁴ Giovanni Cioffi⁵, Andrea Rossi⁶, Catherine M Otto⁷

1- Cardiology Service, CMSR-Veneto Medica. Altavilla Vicentina (VI) Italy

2-Referral Center for Myocardial Diseases, Careggi University Hospital, Florence, Italy

3-Section of Cardiovascular Diseases, University of Brescia, Brescia, Italy.

4-Cardiology, ARC, Azienda Ospedaliera S. Maria degli Angeli, Via Montereale, 24, 33170 Pordenone, Italy.

5-Department of Cardiology, Villa Bianca Hospital, Trento, Italy.

6- Section of Cardiology, Department of Medicine, University of Verona, Italy.

7-University of Washington School of Medicine, Seattle, WA USA

Short Title: Multiparametric Assessment for Severe Aortic Stenosis

Word count: 2,586 excluding title page, abstract, references, figures and tables.

Key words: Aortic stenosis, Echocardiography, Outcome

Address for Correspondence:

Stefano Nistri, MD, PhD

Cardiology Service, CMSR Veneto Medica

Via Vicenza, 204. 36077 Altavilla Vicentina (VI) Italy

Phone:+390444225111

FAX: +390444225199

E-mail: snistr@tin.it

1
2
3
4
5
6
7 **Objective.** To establish whether different criteria to assess severity of aortic stenosis (AS) may
8 have additive prognostic relevance in asymptomatic patients with normal left ventricular function.
9

10
11 **Design.** Retrospective study.
12

13
14 **Setting.** Outpatient echocardiographic laboratories.
15

16
17 **Patients.** One-hundred forty-nine AS patients (74.5±9.4 years, 52% males), with at least one of
18 the following 4 criteria: peak aortic flow velocity (V_{\max}) >4m/sec; mean transvalvular gradient
19 (MG)>40 mm Hg; aortic valve area (AVA) <1 cm²; AVA indexed for body surface area (AVAI) <0.6
20 cm²/m². Mean follow-up duration was 25.9±22.3 months.
21
22

23
24
25 **Main outcome measures.** Combination of all-cause death or aortic valve replacement (AVR).
26

27
28 **Results.** Outcome was better in the 69 patients (46%) with ≤2 criteria, than in the 80 patients with
29 ≥3 criteria (p<0.001); and in patients with neither MG>40 mm Hg nor V_{\max} >4 m/sec compared
30 with those having at least one of these 2 criteria (p<0.001). At univariate Cox survival analysis,
31 MG>40 mmHg and/or V_{\max} >4m/sec were the best predictors for the combined end-point. At
32 multivariate analysis, predictors of outcome were male gender (HR 1.751 CI 95% 1.111-2.758,
33 p=0.016), higher MG (HR per 10 mmHg increase 2.626, CI95% 1.663-4.146), p<0.001) and active
34 smoking (HR 3.84 CI 95% 1.15-12.8, p=0.028). In patients with MG≤40 mmHg, an AVAI <0.4
35 cm²/m² provided further risk stratification (4-year event-free survival 33%, vs. 58% in patients
36 >0.4 cm²/m² (p=0.001).
37
38
39
40
41
42
43
44
45
46
47
48

49 **Conclusions.** Hierarchical prognostic assessment of AS severity favors MG>40 mmHg as the most
50 potent predictors of outcome. However, the convergence of multiple criteria adds predictive
51 accuracy, supporting the need for multiparametric assessment of hemodynamics in asymptomatic
52 patients with severe AS.
53
54
55
56
57

58 **Word count:** 250
59
60

1
2
3 Doppler echocardiography plays a pivotal role in non-invasive hemodynamic assessment of
4
5 aortic stenosis (AS). Among multiple available measures, peak aortic flow velocity (V_{\max}), mean
6
7 transvalvular gradient (MG) and effective aortic valve area, either simple (AVA) or indexed for
8
9 body surface area (AVAI), are recommended for the assessment of the severity of AS. In
10
11 particular, $V_{\max} > 4\text{m/sec}$, $\text{MG} > 40\text{ mm Hg}$, $\text{AVA} < 1\text{ cm}^2$ and $\text{AVAI} < 0.6\text{ cm}^2/\text{m}^2$ have all been
12
13 suggested as cutoffs indicating severe AS. [1-3] However, it has been recently shown that these
14
15 parameters are not interchangeable, resulting into inconsistent estimates of the prevalence of
16
17 severe AS, with potential implication for clinical follow-up and decision making.[4-6] Furthermore,
18
19 while each of these criteria has been utilized for defining AS severity, their relative accuracy in
20
21 predicting outcome is unresolved.
22
23
24
25

26
27 The apparent discrepancies in AS severity measures might be clinically relevant both in
28
29 symptomatic and asymptomatic individuals. In symptomatic patients, inconsistencies among
30
31 different echocardiographic parameters may lead to misinterpretation of symptoms and
32
33 subsequent inappropriate delay of aortic valve replacement (AVR). In asymptomatic patients, such
34
35 discrepancies can result in inappropriate follow-up strategies and hinder appropriate
36
37 management. This is particularly relevant in elderly individuals, in whom interpretation of
38
39 symptoms and management decisions are complicated further by multiple, age-related problems
40
41 associated with AS.[7-9]
42
43
44

45
46 In order to resolve these challenging issues, we therefore chose to assess outcome in
47
48 asymptomatic AS patients with normal left ventricular (LV) ejection fraction and at least one
49
50 echocardiographic criterion for severe AS. The aim of the study was to evaluate whether different
51
52 criteria have variable prognostic relevance in these patients, and whether the presence of
53
54 multiple criteria might hold incremental value in predicting outcome.
55
56
57
58
59
60

METHODS

Patient Population. We enrolled subjects with a diagnosis of AS aged ≥ 21 years, consecutively studied at outpatient echocardiographic laboratories, having at least one of the following 4 criteria: $V_{\max} > 4$ m/sec; $MG > 40$ mm Hg; $AVA < 1$ cm²; $AVAI < 0.6$ cm²/m². Exclusion criteria were: any symptom attributable to AS; left ventricular (LV) ejection fraction $< 50\%$; the presence of additional valvular disease more than mild in severity; the presence of congenital heart disease except bicuspid aortic valve; previous valvular or aortic surgery, primary hypertrophic or restrictive cardiomyopathy; neoplastic disease or significant co-morbidity of potential prognostic impact.

Echocardiographic and Doppler Measurements. Echocardiography was performed with commercially available ultrasound systems. All patients underwent a comprehensive examination including M-mode and two-dimensional echocardiography, with continuous wave, pulsed and color Doppler, by experienced operators. For each measurement, three cardiac cycles were averaged. In all patients the LV end-diastolic and end-systolic volumes (indexed for body surface area) were measured using the biplane Simpson's rule method, from which the LV ejection fraction was calculated.[10] The LV mass (in grams) was calculated using the Devereux formula and then indexed for body surface area. Relative wall thickness was computed as $2 \times$ posterior wall thickness/LV radius at end-diastole.[10]

The LV outflow tract diameter was measured in mid-systole from the parasternal long-axis view below the aortic valve. Pulsed-wave Doppler sampling of the LV outflow tract was performed below the aortic valve at the point where the flow velocity dropped when moving the sample volume from the aortic valve level into the outflow tract, matching the location of LV outflow tract diameter measurement. Maximum velocity and velocity time integral were measured by tracing the modal velocity (middle of the dense signal) for use in the continuity equation and calculation

1
2
3 of stroke volume using an optimal signal . Transvalvular velocities were interrogated by
4
5 continuous-wave Doppler (including a non-imaging transducer) from multiple windows to obtain
6
7 V_{\max} . Maximal instantaneous gradient across the aortic valve was calculated using a modified
8
9 Bernoulli equation; MG was measured by tracing of the velocity curve. AVA was calculated by the
10
11 continuity equation [3] and indexed for body surface area (AVAI). Calcification of the aortic valve
12
13 was qualitatively assessed and classified as previously suggested.[3] Arterial blood pressure was
14
15 measured at the right arm by a trained nurse, using a properly sized cuff sphygmomanometer.
16
17
18

19 **Follow-up and Endpoints.** Follow-up information was obtained from office visits or direct
20
21 interviews with the patients, their relatives or their general practitioner. The endpoint was a
22
23 composite of all-cause mortality and AVR. Mean follow-up duration was 26 ± 22 months (range 4-
24
25 122 months) and was completed in all study patients.
26
27

28
29 Particular attention was given to the information regarding indications for AVR and cause
30
31 of death, so that the reports from in-hospital stay and death certifications were obtained in all
32
33 patients and carefully examined. The primary indications for AVR were classified as (a)
34
35 development of AS-related symptoms, (b) patients with severe AS who developed LV ejection
36
37 fraction $< 50\%$; (c) patients with severe AS undergoing coronary artery bypass graft surgery; and (d)
38
39 patients with severe AS undergoing surgery on the aorta. Causes of death was ascertained by the
40
41 review of reports from in-hospital stay and death certifications.
42
43
44

45 **Statistical methods.** Continuous variables are expressed as mean \pm SD unless otherwise
46
47 specified. Unpaired Student's t-test or one-way analysis of variance were employed for
48
49 comparison of normally distributed data. Chi-square or Fisher's exact test, as appropriate, were
50
51 utilized to compare noncontinuous variables expressed as proportions. Survival curves were
52
53 constructed according to the Kaplan-Meier method, and comparisons were performed using the
54
55 log-rank test. Hazard ratios and 95% confidence intervals were calculated using univariate and
56
57
58
59
60

multivariate Cox proportional hazard regression models. Multivariate analyses were performed with a stepwise forward regression model, by which only variables with a p-value of ≤ 0.05 (based on univariate analysis) were entered into the model; variables included age, gender, hypercholesterolemia, diabetes mellitus, arterial hypertension, coronary artery disease (defined as previous acute coronary syndrome and/or revascularization procedures, or positive stress tests of inducible ischemia, or any coronary artery stenosis $>70\%$ at coronary angiography), LV ejection fraction, LV mass index, V_{max} , MG, AVA, AVAI. All P-values are two-sided and considered significant when <0.05 . Calculations were performed using a SPSS 12.0 software (Chicago, IL).

RESULTS

Baseline patient features. The study group consisted of 149 patients whose main clinical and echocardiographic characteristics are shown in Table 1 .

Table 1: Baseline characteristics of study patients. Data are reported as mean \pm SD (range) unless otherwise specified.

Variable	Patients (n=149)
CLINICAL DATA	
Age (Years)	74.5 \pm 9.4 (40-94)
Male (n;%)	78 (52%)
Height (m)	1.66 \pm 0.1 (1.45-1.9)
Weight (kg)	74 \pm 13 (46-110)
Body surface area (m ²)	1.80 \pm 0.2 (1.2-2.28)
Body mass index (kg/m ²)	26.7 \pm 4.1 (16.5-40.4)
Systolic Blood Pressure (mmHg)	142 \pm 16 (105-185)
Diastolic Blood pressure (mmHg)	79.5 \pm 9.5 (50-110)
Arterial hypertension (n;%)	115 (77%)
Diabetes (n;%)	25 (16.8%)
Hypercholesterolemia (n;%)	57 (38%)

Coronary artery disease	24 (16%)
Current Smoking (n;%)	7 (4.6%)
ECHOCARDIOGRAPHIC DATA	
Left Ventricular end-diastolic diameter (mm)	50.1±5(37-64)
Inter-ventricular septal thickness (mm)	12.9±1.6 (8-18)
Posterior wall thickness (mm)	11.9±1.4 (8-17)
Left ventricular mass (g)	252.9±61 (135-458)
Left ventricular mass index (g/m ²)	141.1±35.3 (80-238)
Relative wall thickness	0.51±0.39 (0.3-0.76)
Left ventricular end-diastolic volume index (ml/m ²)	66±12 (40-90)
Left-ventricular ejection fraction(%)	61.2±5 (50-78)
Stroke volume index (ml/m ²)	44.1±9.6 (26,6-70)
Peak aortic velocity (m/sec)	4.08±0.64 (2.6-6.8)
Mean aortic gradient (mmHg)	41.6±15.5 (13-115)
Aortic valve area (cm ²)	0.88±0.20 (0.45-1.5)
Indexed aortic valve area (cm ² /m ²)	0.45±0.62 (0.16-0.8)

Aortic valve calcification was severe in all subjects. Most patients (111; 74%) were >70 years. AVAI was <0.6 cm²/m² in 142 (95%); 104 patients (70%) had AVA<1 cm², 82 (55%) V_{max} >4m/sec, and 77 (52%) MG>40 mmHg. MG was directly related to V_{max} (R²=0.79, beta 0.89, p<0.001) and inversely to AVA (R²=0.29, beta -0.54, p<0.001). AVAI was only moderately related to AVA (R²=0.28, beta 0.53, p<0.001), V_{max} (R²=0.18, beta -0.43, p<0.001) and MG (R²=0.12, beta -0.35, p<0.001). LV stroke volume indexed for body surface area was higher in patients with MG>40 mmHg (46.7±9.2 ml/m²) than in patients with MG<40 mm Hg (40.9±9 ml/m² ; p<0.001) and was below normal limits (<35 ml/m²) in 22 patients (14.7%).

Outcome. During follow-up (26±22 months, range 4-122 months), a total of 86 patients (58%) either died (n=31;20%) or had AVR (n=55;37%). Survival was 95% at 1 year, 84% at 2 years, 76% at 3 years, 70% at 4 years; survival free of the combined end-point of all-cause mortality and

1
2
3 AVR was 84% at 1 year, 61% at 2 years, 46% at 3 years and 36% at 4 years. AVR was advised due
4 to progression of symptoms in 48 patients or decline of LV ejection fraction (<50%) in 2, rapid
5 progression of AS in 3 patients, and triggered by need for coronary artery revascularization in 2.
6
7
8 The cause of death was of definite cardiovascular origin in 24 patients (including 2 ischemic
9 strokes), of non-cardiac origin in 5 (including 1 with perioperative mortality at noncardiac surgery),
10 and could not be determined in the remaining 2. Event-free survival at 4 years was not different in
11 patients with stroke volume index < or ≥ 35 ml/m² (32% vs 37%, respectively, p=0.78) .
12
13
14
15
16
17
18

19 **Relevance of multiparametric evaluation of AS to outcome.** Event- free survival was
20 significantly better in the 69 patients (46%) with ≤ 2 positive criteria for severe AS, compared with
21 the remaining 80 patients who had ≥ 3 criteria (p<0.001) (Figure 1). There was a clear, additive
22 trend towards a worse prognosis based on the number of positive criteria. In particular, survival
23 was better for AS patients who had neither MG>40 mmHg nor $V_{\max} > 4$ m/sec compared with those
24 who had at least one of these 2 criteria [58% (SE 8%) vs 19% (SE 11%) at 4 years]. Moreover, in 73
25 patients (49%) with MG \leq 40 mmHg, an AVAI <0.4 cm²/m² (i.e.: the median value for AVAI) was
26 associated with a 4 year event-free survival of 33% compared to 58% (P=0.001) (Figure 2).
27
28
29
30
31
32
33
34
35
36
37

38 At univariate Cox survival analysis, MG>40 mm Hg, $V_{\max} > 4$ m/sec or their combination
39 showed the best predictive capability for the combined end-point (Figure 3). At multivariate Cox
40 survival analysis, the three independent predictors of outcome were male gender (HR 1.75, CI 95%
41 1.11-2.76; p=0.016), increased MG (HR per 10 mmHg increase 2.62, CI95% 1.66-4.15; p<0.001) and
42 active smoking (HR 3.84, CI 95% 1.15-12.8; p=0.028). Predictors did not change after excluding the
43 5 patients without primary indication to AVR (data not shown). Of note, patients with ≥ 3 variables,
44 compared to those with ≤ 2 , had an almost 3-fold increase in likelihood for the combined end-point
45 (HR 2.88, CI 95% 1.68-4.94; p<0.001).
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

Management of severe AS in the absence of symptoms is controversial and challenging [1-3, 5, 11-13]. Because of the natural history of severe asymptomatic AS, accurate echocardiographic grading is crucial for clinical decision making. Nevertheless, echocardiographic methods employed to this purpose have shown limitations in predicting symptom onset and outcome. Specifically, the relative predictive accuracy of the most commonly used parameters used to define severe AS (i.e.: $V_{\max} > 4$ m/sec, or $MG > 40$ mm Hg, or $AVA < 1$ cm², or $AVAI < 0.6$ cm²/m²) is unresolved. As a novel contribution we thus planned to assess the value of multiparametric echocardiographic evaluation in asymptomatic AS patients with ≥ 1 criterion for severe AS and normal LV ejection fraction. Our findings show that (i) $V_{\max} > 4$ m/sec and $MG > 40$ mm Hg predicted the combined end-point of death or AVR more effectively than the area-related criteria, with $MG > 40$ mm Hg resulting as the only independent echocardiographic predictor at multivariable analysis; (ii) the positivity for multiple criteria had a significant additive effect compared to any single criterion alone, in predicting worse event-free survival; and that (iii) in patients with $MG \leq 40$ mm Hg, an extreme narrowing of $AVAI < 0.4$ cm²/m² provided increasing predictive value.

Increasing V_{\max} has been related to the natural history of AS in multiple studies, over a broad range of values ranging from mild to very severe increase in aortic peak velocity. [12-16] Consistently, rate of progression of AS severity in terms of yearly changes in V_{\max} , is prognostically relevant in asymptomatic patients with any grade of AS severity, both from referral centers and outpatient facilities.[3,5,9] Due to the strict relation between V_{\max} and MG , the prognostic superiority over area-related parameters is similar for V_{\max} and MG in the present study. However, because obstruction related to AS persists throughout the systolic ejection period, the relationship between V_{\max} and mean gradient depends on the shape of the velocity curve, which varies with

1
2
3 stenosis severity and flow rate. [3] Thus, since MG is assessed from multiple mean instantaneous
4
5 calculations around the whole continuous-wave Doppler envelope, it retains informations of the
6
7 waveform shape, and it is likely more representative of the severity of AS than V_{\max} . [17, 18] Thus,
8
9 MG constitutes the optimal indicator of severity of obstruction by retaining all these information,
10
11 and is more reliably related to invasive hemodynamics than peak aortic gradient [3,6, 17-20].
12
13

14
15 Conversely, conflicting results have been reported regarding the prognostic significance of
16
17 AVA. Some recent studies, in fact, have demonstrated that AVA is not necessarily related to
18
19 mortality [11, 15,16]. These results, however, could have been at least partially biased by referral
20
21 criteria segmenting a priori subsets of AS patients enrolled in tertiary center studies. Indeed, a
22
23 recent community study including AS patients without life-threatening comorbid conditions, with
24
25 any degree of AS severity, and a wide range of clinical presentations, demonstrated $AVA < 1 \text{ cm}^2$ to
26
27 be the only measure of AS severity independently predictive of survival on medical treatment.
28
29 [21] Since AVA is related to cardiac output and therefore to body size [22], the correction for body
30
31 surface area has been proposed in the early 1960's, with the advantage that indexing AVA for
32
33 body surface area provides a measure of severity of aortic valve narrowing which also
34
35 incorporates stroke volume index. A value of $AVAI < 0.7 \text{ cm}^2/\text{m}^2$ is generally proposed as a cut-off
36
37 for severe AS. [23] Intriguingly, a similar AVAI value of $\leq 0.6 \text{ cm}^2/\text{m}^2$ has been shown to correlate
38
39 with a LV stroke work loss of $\geq 30\%$. [24] Recently, in 103 consecutive, asymptomatic patients with
40
41 $AVA < 1 \text{ cm}^2$ and a small average body surface area ($1.50 \pm 0.15 \text{ m}^2$), $AVAI < 0.6 \text{ cm}^2/\text{m}^2$ was shown
42
43 to be a significant predictor of outcome. [25]
44
45
46
47
48
49

50 For each value of AVA, different situations can be detected in terms of transaortic flow
51
52 rates and pressure gradients, giving rise to a discordance between gradients and AVA. While such
53
54 discrepancies might represent an inherent inconsistency of the criteria present in most guidelines,
55
56 or reflect small body size or measurement errors [4,6] an increasing body of evidence now
57
58
59
60

1
2
3 supports the entity of low gradient severe AS with paradoxical low-flow (i.e.: reduced stroke
4
5 volume index with normal ejection fraction) whose natural history seems to be comparable to
6
7 severe narrowing of the AVA coexisting with high flow and high gradient.[11,26-29] Indeed, we
8
9 observed no differences in outcome in our patients with low or normal stroke volume index.
10
11

12 The findings of the present study may have several implications for the hierarchical use of
13
14 primary hemodynamic parameters recommended for assessment of risk associated with severe
15
16 AS. The independent accuracy of $MG > 40$ mm Hg underscores the need for accurate velocity
17
18 recording from multiple acoustic windows, in order to optimize the assessment of aortic
19
20 velocities, which remains the more robust and reproducible measurement in daily practice.
21
22 Moreover, convergence of more measures should be interpreted as a further increase in
23
24 predictive capability, with practical influences on follow-up and decision making. In patients with
25
26 $MG \leq 40$ mmHg, who were characterized by lower stroke volume index, the same hierarchical
27
28 approach can be proposed to identify those at greater risk. Indeed, further stratification of these
29
30 patients based on an AVAI threshold of $0.4 \text{ cm}^2/\text{m}^2$ provided a clinically meaningful predictor of the
31
32 combined end-point, consistent with a recently proposed classification of severe asymptomatic
33
34 AS. [11]
35
36
37
38
39

40 Irrespective of the parameter utilized for its assessment, our findings confirm that the
41
42 prognosis of severe, asymptomatic AS is dismal.[15,16,30] Thus, it is important not to
43
44 underestimate the hemodynamic severity of AS in patients with less than expected MG or V_{\max} .
45
46 [25-30] Maximal care should be paid in assessing each of the components of the continuity
47
48 equation, particularly as regards consistency of LV stroke volume as assessed by Doppler with that
49
50 assessed by evaluation of LV ejection fraction, but also to optimize hemodynamic systemic
51
52 conditions know to potentially affect AVA (i.e.: systemic arterial hypertension). Furthermore, in
53
54 selected patients, additional diagnostic tools (such as magnetic resonance, computed tomography
55
56
57
58
59
60

1
2
3 or cardiac catheterization) should be taken in consideration for proper assessment of severity.
4

5 [28,30]
6

7
8 This study has several limitations. Although the baseline data were prospectively collected
9
10 in consecutive patients with AS referred to the echocardiographic laboratory, the outcome data
11
12 were retrospectively obtained. Moreover, we did not assess the rate of hemodynamic progression
13
14 of AS in our patients, which have been shown to be an independent determinant of outcome in
15
16 multiple clinical setting. Similarly, symptomatic status was not objectively assessed.. Future
17
18 prospective studies are warranted to assess the value of multiparametric assessment in AS in the
19
20 light of disease progression and n objective evaluation of functional capacity.
21
22
23
24
25

26 **Conflict of interest.** None
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1: Kaplan-Meier event-free (overall-mortality and AVR) survival for patients with one or two criteria (n=69) and patients with three or four criteria (n=80).

Figure 2: Kaplan-Meier event-free (overall-mortality and AVR) survival for patients with MG > 40 mmHg and ≤40 mmHg with AVAI < or ≥0.4cm²/m².

Figure 3: Univariate Cox regression analysis for the combined end-point (overall mortality and AVR) for each parameter and their combination (Hazard Ratio ± 95% confidence interval).

REFERENCE LIST


1. Vahanian A, Alfieri O, Andreotti F et al Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2012;**33**:2451-96
2. Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Valvular Heart Disease). *J Am Coll Cardiol*. 2006;**48**:e1–e148.
3. Baumgartner H, Hung J, Bermejo j et al, Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. *European Journal of Echocardiography* 2009; **10**: 1–25
4. Minners J, Allgeier M, Gohlke-Baerwolf C, et al Inconsistent grading of aortic valve stenosis by current guidelines: haemodynamic studies in patients with apparently normal left ventricular function. *Heart* 2010;**96**:1463– 8.
5. Dal-Bianco JP, Khanderia BK, Mookadam F et al. Management of asymptomatic severe aortic stenosis. *J Am Coll Cardiol*; 2008;**52**:1279-92
6. Flachskampf FA. Severe aortic stenosis with low gradient and apparently preserved left ventricular systolic function-under-recognized or overdiagnosed? *Eur Heart J*;2008;**29**:966-8
7. Bach DS, Siao D, Girard SE, Duvernoy C, McCallister BD, Gualano SK. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement. The

- 1
2
3 potential role of subjectively overestimated operative risk. *Circ Cardiovasc Qual Outcomes*
4
5 2009;**2**:533-539
6
7
8 8. Schueler R, Hammerstingl C, Sinning JM, Nickenig G, Omran H. Prognosis of octogenarians
9
10 with sever aortic valve stenosis at high risk for cardiovascular surgery. *Heart* 2010;**96**:1831-
11
12 1836
13
14
15 9. Nistri S, Faggiano P, Olivotto I et al. Hemodynamic progression and outcome of
16
17 asymptomatic aortic stenosis in primary care. *Am J Cardiol* 2012;**109**:718-23
18
19
20 10. Lang RM, Bierig M, Devereux RB, et al; American Society of Echocardiography's
21
22 Nomenclature and Standards Committee; Task Force on Chamber Quantification; American
23
24 College of Cardiology Echocardiography Committee; American Heart Association; European
25
26 Association of Echocardiography, European Society of Cardiology. Recommendations for
27
28 chamber quantification: a report from the American Society of Echocardiography's
29
30 Guidelines and Standards Committee and the Chamber Quantification Writing Group,
31
32 developed in conjunction with the European Association of Echocardiography, a branch of
33
34 the European Society of Cardiology. *Eur J Echocardiogr* 2006;**7**:79-108.
35
36
37
38 11. Lancellotti P, Magne J, Donal E et al Clinical outcome in asymptomatic severe aortic
39
40 stenosis. Insights from the new proposed grading classification. *J Am Coll Cardiol*
41
42 2012;**59**:224-32
43
44
45 12. Kitai T, Honda S, Okada Y et al Clinical outcomes in non-surgically managed patients with
46
47 very severe versus severe aortic stenosis. *Heart* 2011;**97**:2029-32
48
49
50 13. Monin JL, Lancellotti P, Monchi M, et al. Risk score for predicting outcome in patients with
51
52 asymptomatic aortic stenosis. *Circulation* 2009;**120**:69 –75.
53
54
55
56
57
58
59
60

- 1
2
3 14. Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic
4
5 stenosis. Clinical, echocardiographic, and exercise predictors of outcome. *Circulation*
6
7 1997;**95**:2262–70
8
- 9
10 15. Rosenhek R, Zilberszac R, Schemper M, et al. Natural history of very severe aortic stenosis.
11
12 *Circulation* 2010;**121**:151-6.
13
- 14
15 16. Pellikka PA, Sarano ME, Nishimura RA, Malouf JF, Bailey KR, Scott CG, Barnes ME, Tajik AJ.
16
17 Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis
18
19 during prolonged follow-up. *Circulation* 2005;**111**:3290-3295
20
21
- 22 17. Chamber JB. Aortic Stenosis. *Eur J Echocardiogr* 2009;**10**:111-9
23
- 24 18. Rajani R, Hancock J, Chambers JB. The art of assessing aortic stenosis. *Heart* 2012;**98**:iv14–
25
26 iv22
27
- 28
29 19. Nishimura RA, Carabello BA, Hemodynamics in the cardiac catheterization laboratory of the
30
31 21st Century. *Circulation*. 2012;**125**:2138-2150
32
- 33
34 20. Geske JB, Cullen MW, Sorajja P, MD, et al , Assessment of left ventricular outflow gradients.
35
36 Hypertrophic cardiomyopathy versus aortic valvular stenosis. *J Am Coll Cardiol Intv*
37
38 2012;**5**:675– 81
39
- 40
41 21. Malouf J, Le Tourneau T, Pellikka P et al. Aortic valve stenosis in community medical
42
43 practice: determinants of outcome and implications for aortic valve replacement. *J Thorac*
44
45 *Cardiovasc Surg* 2012;**144**:1421-7
46
47
- 48 22. Rahimtoola SH. Determining that aortic valve stenosis is severe: back-to-the-future. *J Am*
49
50 *Coll Cardiol Img* 2010;**3**:563-6
51
- 52
53 23. Braunwald E, Roberts WC, Goldblatt A, et al. Clinical staff conference; aortic stenosis:
54
55 Physiological, pathological and clinical concepts. *Ann Int Med* 1963;**58**:494-522
56
57
58
59
60

- 1
2
3 24. Tobin JR, Rahimtoola SH, Blundell PE et al Percentage of left ventricular stroke work loss: a
4
5 simple hemodynamic concept for estimation of severity in valvular aortic stenosis.
6
7 *Circulation* 1967;**35**:868-79
8
9
10 25. Saito T, Muro T, Takeda H et al. Prognostic value of aortic valve area index in asymptomatic
11
12 patients with severe aortic stenosis. *Am J Cardiol* 2012;**110**:93-7
13
14
15 26. Clavel M-A, Dumesnil JG, Capoulade R et al Outcome of patients with aortic stenosis, small
16
17 valve area, and low-flow, low-gradient despite preserved left ventricular ejection fraction. *J*
18
19 *Am Coll Cardiol* 2012;**60**:1259-67
20
21
22 27. Barasch E, Fan D, Chukwu EO, et al. Severe isolated aortic stenosis with normal left
23
24 ventricular systolic function and low transvalvular gradients: pathophysiologic and
25
26 prognostic insights. *J Heart Valve Dis* 2008;**17**:81– 8.
27
28
29 28. Lancellotti P, Donal E, Magne J, et al. Impact of global left ventricular afterload on left
30
31 ventricular function in asymptomatic severe aortic stenosis: a two-dimensional speckle-
32
33 tracking study. *Eur J Echocardiogr* 2010;**11**:537– 43.
34
35
36 29. Rossi A, Nistri S, Cioffi G et al. Severe aortic valve stenosis with normal left ventricular
37
38 function and low vs. high pressure gradient: Different hemodynamic profiles but similar
39
40 clinical presentation, comorbidity and outcome. *Int J Cardiol.* 2012 [Epub ahead of print]
41
42
43 30. Herrmann S, Stork S, Niemann M, et al. Low-gradient aortic valve stenosis: Myocardial
44
45 fibrosis and its influence on function and outcome. *J Am Coll Cardiol* 2011;**58**:402–12.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




≤ 2 criteria	65	52	31	18	13
≥ 3 criteria	74	48	24	10	5

190x142mm (300 x 300 DPI)

Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



190x142mm (300 x 300 DPI)

Review Only




Fig 4

254x190mm (300 x 300 DPI)

Review Only